WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: C07F 9/06, C07D 311/04, A61K 9/00, 31/66, 31/35

(11) International Publication Number:

WO 00/44757

(43) International Publication Date:

3 August 2000 (03.08.00)

(21) International Application Number:

PCT/US00/01923

A1

(22) International Filing Date:

26 January 2000 (26.01.00)

(30) Priority Data:

60/117,567 60/118,198 27 January 1999 (27.01.99) US 1 February 1999 (01.02.99) US

(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Applications

US Filed on

60/117,567 (CIP) 27 January 1999 (27.01.99)

US Filed on

60/118,198 (CIP) 1 February 1999 (01.02.99)

(71) Applicant (for all designated States except US): ZIELINSKI LABORATORY [US/US]; Suite C, 10366 Rosell Street, San Diego, CA 92121 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): ZIELINSKI, Jan, E. [DE/US]; 820 Sycamore Avenue, #105, Vista, CA 92083 (US).

(74) Agent: HAILE, Lisa, A.; Gary Cary Ware & Friedenrich LLP, Suite 1600, 4365 Executive Drive, San Diego, CA 92121-2189 (US).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

With international search report.

(54) Title: HESPERITIN PRO-FORMS WITH ENHANCED BIOAVAILABILITY

(57) Abstract

A hesperitin pro-form is provided. The invention provides both a hydrophilic and lipophilic hesperetin pro-form. A pharmaceutical composition is provided which is suitable for topical or oral administration in an individual, the composition comprising a hydrophilic or oral administration in an individual, the composition is also provided which is suitable for topical or oral administration in an individual, the composition including a lipophilic hesperetin pro-form and a pharmaceutically acceptable carrier. A method is provided for treating a subject having or at risk of having a cell proliferative disorder, including administering to the subject a therapeutically effective amount of a hesperetin pro-form.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| AL AM AT AU AZ BA BB BE BF BG BJ BR CA CF CG CH CI CM CN CU CZ DE DK EE | Albania Armenia Australia Australia Australia Bosnia and Herzegovina Barbados Belgium Burkina Faso Bulgaria Benin Brazil Belarus Canada Central African Republic Congo Switzerland Côte d'Ivoire Cameroon China Cuba Czech Republic Germany Denmark Estonia | ES FI FR GA GB GE GN GR HU IE IL IS IT JP KE KG KP KR LC LI LK LR | Spain Finland France Gabon United Kingdom Georgia Ghana Guinea Greece Hungary Ireland Israel Iceland Italy Japan Kenya Kyrgyzstan Democratic People's Republic of Korea Republic of Korea Republic of Korea Kazakstan Saint Lucia Liechtenstein Sri Lanka Liberia | LS LT LU LV MC MD MG MK ML MN MR MW NE NL NO NZ PL PT RO RU SD SE SG | Lesotho Lithuania Luxembourg Latvia Monaco Republic of Moldova Madagascar The former Yugoslav Republic of Macedonia Mali Mongolia Mauritania Malawi Mexico Niger Netherlands Norway New Zealand Poland Portugal Romania Russian Federation Sudan Sweden Singapore | SI SK SN SZ TD TG TJ TM TR TT UA UG US VN YVU ZW | Slovenia Slovakia Senegal Swaziland Chad Togo Tajikistan Turkenenistan Turkey Trinidad and Tobago Ukraine Uganda United States of America Uzbekistan Viet Nam Yugoslavia Zimbabwe |
|---|---|---|---|--|---|--|---|
|---|---|---|---|--|---|--|---|